Detalles de la búsqueda
1.
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.
J Infect Dis
; 205(1): 87-96, 2012 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22180621
2.
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.
PLoS Med
; 7(8)2010 Aug 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-20711481
3.
Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210.
AIDS Res Hum Retroviruses
; 35(8): 691-697, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31099252
4.
Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.
AIDS
; 26(11): 1345-54, 2012 Jul 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-22441252
5.
No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.
J Acquir Immune Defic Syndr
; 59(3): 229-35, 2012 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22083073
6.
Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects.
Antimicrob Agents Chemother
; 51(7): 2351-8, 2007 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17452489
7.
Clinical considerations in study designs that use cotinine as a biomarker.
Biomarkers
; 8(3-4): 187-203, 2003.
Artículo
en Inglés
| MEDLINE | ID: mdl-12944172
Resultados
1 -
7
de 7
1
Próxima >
>>